Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Tumor Biology

Abstract SY41-04: Immune suppression by T cell exclusion in pancreatic cancer

Douglas T. Fearon
Douglas T. Fearon
Cold Spring Harbor Laboratory and Weill Cornell Medical College, New York, NY.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM2015-SY41-04 Published August 2015
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA

Abstract

In 1960, Klein and colleagues found that when mice developed primary methylcholanthrene-induced sarcomas, they also developed an acquired immune resistance mediated by lymph node cells to a secondary challenge comprised of cancer cells derived from the primary tumor. The paradoxical and critical finding of the study was that this anti-cancer immune response did not control the growth of the primary tumor, despite its ability to prevent the establishment of a secondary tumor comprised of cancer cells derived from the primary tumor. The primary tumor evaded immune control by establishing an immune suppressive tumor microenvironment (TME).

Unambiguous evidence for the inability in humans of a systemic immune response to eliminate immunogenic cancer cells was provided by Boon's studies thirty years later of the antigens that elicit specific CD8+ T cell responses in melanoma patients. Cloned CD8+ T cells from a melanoma patient were used to identify the antigen expressed by that patient's cancer: MAGE-A1. The explicit demonstration of the co-existence of a progressing melanoma with melanoma-specific T cells in this patient implicitly raised the question of why the T cells did not control the growth of the cancer. Moreover, Rosenberg and colleagues reported evidence of disease recurrence in melanoma patients despite very high levels of vaccine-induced circulating T cells and no evidence of antigen loss.

The discovery of melanoma-specific T cells in patients led not only to vaccine strategies to increase the frequency of cancer-specific T cells in patients, but also to a more direct means for accomplishing this goal, that of adoptively transferring large numbers of in vitro expanded tumor-infiltrating lymphocytes. This approach has shown some efficacy, but has not had the dramatic success of adoptively transferring virus-specific CD8+ T cells to immunodeficient bone marrow transplant recipients with CMV infection or EBV-associated lymphoproliferative disorders. Differences in the microenvironments of virally infected tissues and cancers must account for these distinct outcomes.

The more recent strategy of enhancing the function of effector T cells by targeting CTLA-4 and PD-1, immunoregulatory receptors on T cells, has been successful in subsets of patients with melanoma, NSCLC, bladder cancer, and renal cell cancer. Nevertheless, it has become apparent that even if these T cell checkpoint antagonists overcome some of the immune suppressive effects of the TME, there must be other, more fundamental inhibitory reactions in the TME to explain why most patients, especially those with colorectal cancer (CRC), ovarian cancer, prostate cancer, and pancreatic ductal adenocarcinoma (PDAC) do not exhibit objective responses to these therapies.

A clue to the nature of this dominant immune suppression mediated by the TME comes from studies that have examined the spatial relationship of CD8+ effector T cells to cancer cells in three of the tumors that do not respond to anti-PD-1/anti-PD-L1: CRC, ovarian cancer and PDA. In each of these cancers, CD8+ T cells are excluded from cancer cell nests, and correlates with a poor long term clinical outcome. Thus, the TME can limit the capacity of T cells to accumulate amongst cancer cells, and one must conclude that until this problem is overcome, the full potential of other approaches to T cell-mediated tumor immunotherapy will not be realized.

Recent studies have begun to explain how this form of immune suppression is mediated. Pre-clinical studies in mouse models of cancer now implicate the major stromal cell types of the TME, cancer-associated fibroblasts (CAFs) and myelomonocytic cells as being responsible for restricting the accumulation of T cells in the vicinity of cancer cells. As would be predicted, overcoming this restriction has revealed the anti-tumor effects of T cell checkpoint antagonists that had been ineffective when administered as monotherapy.

I will discuss my group's recent studies of how the CAF mediates the exclusion of T cells in an autochthonous moue model of PDAC. The discovery the mechanism of exclusion has led to a potential therapeutic approach that revealed the existence of a previously unsuspected spontaneous anti-cancer immune response in these mice, and uncovered the efficacy of the anti-PD-L1 T cell checkpoint antagonist.

Citation Format: Douglas T. Fearon. Immune suppression by T cell exclusion in pancreatic cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr SY41-04. doi:10.1158/1538-7445.AM2015-SY41-04

  • ©2015 American Association for Cancer Research.
Previous
Back to top
Cancer Research: 75 (15 Supplement)
August 2015
Volume 75, Issue 15 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract SY41-04: Immune suppression by T cell exclusion in pancreatic cancer
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract SY41-04: Immune suppression by T cell exclusion in pancreatic cancer
Douglas T. Fearon
Cancer Res August 1 2015 (75) (15 Supplement) SY41-04; DOI: 10.1158/1538-7445.AM2015-SY41-04

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract SY41-04: Immune suppression by T cell exclusion in pancreatic cancer
Douglas T. Fearon
Cancer Res August 1 2015 (75) (15 Supplement) SY41-04; DOI: 10.1158/1538-7445.AM2015-SY41-04
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Tumor Biology

  • Abstract SY34-04: Do we need to know what pO2 hypoxia is
  • Abstract SY28-04: Rational incorporation of novel agents into multimodality treatment of glioma and neuroblastoma
  • Abstract SY28-02: Connections in the BRCA1-BRCA2 pathway of homologous recombination: Implications for breast cancer development and treatment
Show more 3

Oral Presentations - Invited Abstracts

  • Abstract SY28-02: Connections in the BRCA1-BRCA2 pathway of homologous recombination: Implications for breast cancer development and treatment
  • Abstract SY34-04: Do we need to know what pO2 hypoxia is
  • Abstract SY34-02: The impact of O2 availability on human cancer
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement